Abbott Laboratories
NYSEABT cost to borrow surges 146% in one week to 0.43%, signaling tightening loan supply despite low short interest of 1.27% of float.
A new long-form analysis for ABT this week — anomalies vs the company's own history, peer comparisons, news context, and the full data picture. Premium subscribers only.
Read on ORTEX →Sign up for premiumAbbott Laboratories enters the week with its options market sending the most bullish signal in twelve months — even as the stock drifts near its monthly lows and the broader medical-device peer group sells off…
Snapshot as of 23 Jun 2026
Abbott Laboratories is down nearly 5% over the past month to $86.67, but company insiders and the Street's bulls are treating the decline as an entry point — even as the options market quietly rotates more bullish than…
Options traders have turned their most bullish in a year on ABT. The put/call ratio hit 0.71 on May 12 — a 52-week low — falling 2.16 standard deviations below its 20-day mean of 0.88. That's the sharpest swing toward…
ABT heads into the back half of April with insiders putting money to work at a stock that has fallen nearly 26% year-to-date — even as a wave of analyst target cuts follows the company's Q1 earnings miss. The most…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ABT — free to start on ORTEX.
Sign up for free →Open ABT on ORTEX